Assessment of Brand Name Prescribing of Biologics (IRAS Ref. 226131) Study

A survey to evaluate the extent to which national recommendations on brand name prescribing of all biological DMARDS including biosimilars are used to manage rheumatological conditions within acute trusts in the UK are being complied with.

Registration for the study has closed.

Study Options